News

Boehringer Ingelheim Partners with Weill Cornell Medicine to Develop New COPD Treatments

Boehringer Ingelheim is partnering with Weill Cornell Medicine to discover new treatment approaches to potentially halt or reverse the progression of chronic obstructive pulmonary disease (COPD). The three-year cooperative agreement will combine the research of Weill Cornell Medicine’s Department of Genetic Medicine in novel therapeutic concepts for airway repair…

Aerobika Device Shows Promise as Treatment for Bronchiectasis as Well as COPD

The Aerobika device, which Monaghan Medical Corporation (MMC) developed to ease symptoms of chronic obstructive pulmonary disease (COPD), may also be effective in patients with non-cystic fibrosis (CF) bronchiectasis, according to a study. The research, “Non-Cystic Fibrosis Bronchiectasis: Regional Abnormalities And Response To Airway Clearance Therapy Using Pulmonary Functional…